Perjeta 420 mg/14 ml (IV Infusion)
14 ml vial: ৳ 215,080.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pertuzumab |
| Company | Roche bangladesh ltd |
Indications
- Treatment of HER2-positive metastatic breast cancer
- Neoadjuvant treatment of HER2-positive early stage breast cancer
- Adjuvant treatment of HER2-positive early breast cancer
Pharmacology
- Binds to HER2 receptor
- Inhibits HER2 interaction with other HER family members
- Affects HER signaling pathway
Dosage & Administration
- Initial dose: 840 mg
- Subsequent dose: 420 mg
- Administered as intravenous infusion
- Different dosing for metastatic, neoadjuvant, and adjuvant treatments
Interaction
- No observed drug-drug interactions with specific medications
Contraindications
- Known hypersensitivity to pertuzumab or its excipients
Side Effects
- Common adverse reactions include diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy
Pregnancy & Lactation
- Verify pregnancy status before initiation
- No information about presence in human milk or effects on breastfed infants
Precautions & Warnings
- Monitor for infusion-related reactions
- Monitor for hypersensitivity reactions/anaphylaxis
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store in refrigerator at 2°C to 8°C
- Keep vial in outer carton to protect from light